1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-178. PMID:
11857671.
2. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-336. PMID:
12811491.
3. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-1314. PMID:
17049716.
4. Lugo Salcedo F, Sánchez Borrego R, Group GU. Assessment of female prevalence of overactive bladder (OAB) in Barcelona using a self-administered screening questionnaire: the Cuestionario de Autoevaluación del Control de la Vejiga (CACV). Int Urogynecol J Pelvic Floor Dysfunct 2013;24:1559-1566.
5. Kogan MI, Zachoval R, Ozyurt C, Schafer T, Christensen N. Epidemiology and impact of urinary incontinence, overactive bladder, and other lower urinary tract symptoms: results of the EPIC survey in Russia, Czech Republic, and Turkey. Curr Med Res Opin 2014;30:2119-2130. PMID:
24932562.
6. Lee YS, Lee KS, Jung JH, Han DH, Oh SJ, Seo JT, et al. Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study. World J Urol 2011;29:185-190. PMID:
19898824.
7. Mauseth SA, Skurtveit S, Spigset O. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database. Acta Obstet Gynecol Scand 2013;92:1208-1215. PMID:
23763552.
8. Michel MC, Schneider T, Krege S, Goepel M. Does gender or age affect the efficacy and safety of tolterodine? J Urol 2002;168:1027-1031. PMID:
12187215.
9. Richter HE, Burgio KL, Chai TC, Kraus SR, Xu Y, Nyberg L, et al. Predictors of outcomes in the treatment of urge urinary incontinence in women. Int Urogynecol J Pelvic Floor Dysfunct 2009;20:489-497. PMID:
19183825.
10. Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, et al. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. Urology 2006;68:318-323. PMID:
16904444.
11. Jeong SJ, Homma Y, Oh SJ. Korean version of the overactive bladder symptom score questionnaire: translation and linguistic validation. Int Neurourol J 2011;15:135-142. PMID:
22087422.
12. Choo MS, Ku JH, Lee JB, Lee DH, Kim JC, Kim HJ, et al. Cross-cultural differences for adapting overactive bladder symptoms: results of an epidemiologic survey in Korea. World J Urol 2007;25:505-511. PMID:
17569056.
13. Sang JH, Park HM. Survey on the prevalence of overactive bladder in healthy Korean postmenopausal women. J Korean Soc Menopause 2012;18:60-66.
14. Coyne KS, Sexton CC, Bell JA. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn 2013;32:230-237. PMID:
22847394.
15. Seim A, Hoyo C, Ostbye T, Vatten L. The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study. BJU Int 2005;96:88-92. PMID:
15963127.
16. Yoshida M, Miyamae K, Iwashita H, Otani M, Inadome A. Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology 2004;63:17-23.
17. Koskimäki J, Hakama M, Huhtala H, Tammela TL. Association of smoking with lower urinary tract symptoms. J Urol 1998;159:1580-1582. PMID:
9554358.
18. Tähtinen RM, Auvinen A, Cartwright R, Johnson TM 2nd, Tammela TL, Tikkinen KA. Smoking and bladder symptoms in women. Obstet Gynecol 2011;118:643-648. PMID:
21860295.
19. Knuutinen A, Kokkonen N, Risteli J, Vähäkangas K, Kallioinen M, Salo T, et al. Smoking affects collagen synthesis and extracellular matrix turnover in human skin. Br J Dermatol 2002;146:588-594. PMID:
11966688.
20. Baron JA, La Vecchia C, Levi F. The antiestrogenic effect of cigarette smoking in women. Am J Obstet Gynecol 1990;162:502-514. PMID:
2178432.
21. Chung MS, Chuang YC, Lee JJ, Lee WC, Chancellor MB, Liu RT. Prevalence and associated risk factors of nocturia and subsequent mortality in 1,301 patients with type 2 diabetes. Int Urol Nephrol 2014;46:1269-1275. PMID:
24595602.
22. de Boer TA, Slieker-ten Hove MC, Burger CW, Vierhout ME. The prevalence and risk factors of overactive bladder symptoms and its relation to pelvic organ prolapse symptoms in a general female population. Int Urogynecol J Pelvic Floor Dysfunct 2011;22:569-575.
23. Al-Shaiji TF, Radomski SB. Relationship between body mass index and overactive bladder in women and correlations with urodynamic evaluation. Int Neurourol J 2012;16:126-131. PMID:
23094218.
24. Ohgaki K, Horiuchi K, Kondo Y. Association between metabolic syndrome and male overactive bladder in a Japanese population based on three different sets of criteria for metabolic syndrome and the overactive bladder symptom score. Urology 2012;79:1372-1378. PMID:
22656415.
25. Kupelian V, McVary KT, Kaplan SA, Hall SA, Link CL, Aiyer LP, et al. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston area community health survey. J Urol 2013;189:S107-S114. PMID:
23234611.
26. Uzun H, Yilmaz A, Kemik A, Zorba OU, Kalkan M. Association of insulin resistance with overactive bladder in female patients. Int Neurourol J 2012;16:181-186. PMID:
23346484.
27. Uzun H, Zorba OU. Metabolic syndrome in female patients with overactive bladder. Urology 2012;79:72-75. PMID:
22014972.
28. Lee WC, Chien CT, Yu HJ, Lee SW. Bladder dysfunction in rats with metabolic syndrome induced by long-term fructose feeding. J Urol 2008;179:2470-2476. PMID:
18433789.
29. Tong YC, Cheng JT. Alteration of M2, 3-muscarinic receptor protein and mRNA expression in the bladder of the fructose fed obese rat. J Urol 2007;178:1537-1542. PMID:
17707055.